MedTrace Logo

Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer

NCT02785627 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2016-05-30

No results posted yet for this study

Summary

The ANTELOPE trial is a longitudinal observational clinical study of changes in bone density, structure and strength over 12 months in men receiving treatment for prostate cancer. Three groups (n = 30 per group) will be compared, with bone assessments at baseline and 12 months. Allowing for a 18 month recruitment period, 12 months follow-up and data analysis, the total study length will be 3 years. The groups comprise:

Group A - Men with prostate cancer starting ADT

Group B - Men with newly diagnosed hormone sensitive metastatic prostate cancer, about to start (or have started within the past 3 months) ADT and who will undergo chemotherapy with docetaxel and prednisolone

Group C - Age-matched men without prostate cancer

Conditions

Interventions

OTHER

Comprehensive bone health assessment

Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius

Sponsors & Collaborators

  • Sheffield Teaching Hospitals NHS Foundation Trust

    collaborator OTHER

  • Weston Park Hospital Cancer Charity

    collaborator OTHER

  • Prof Janet Brown

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-03-31
Completion
2019-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785627 on ClinicalTrials.gov